Literature DB >> 7532545

Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.

K Samoto1, K Ikezaki, M Ono, T Shono, K Kohno, M Kuwano, M Fukui.   

Abstract

To examine which growth factors correlate with neovascularization in human brain tumors, the mRNA levels of transforming growth factor alpha, transforming growth factor beta, basic fibroblast growth factor, and vascular endothelial growth factor (VEGF) genes were determined by a Northern blot analysis in surgically obtained human gliomas and meningiomas. The vascular development was determined by counting the number of microvessels which were immunostained with von Willebrand factor. We normalized the growth factor mRNA levels versus the glyceraldehyde phosphate dehydrogenase mRNA level. In the 17 gliomas and 16 meningiomas examined, the mRNA of transforming growth factors alpha and beta, basic fibroblast growth factor, and VEGF were expressed at various levels. Among those 4 growth factors, the mRNA levels of VEGF, but not those of transforming growth factors alpha and beta and basic fibroblast growth factor, correlated significantly with vascularity in both gliomas (correlation coefficient r = 0.499; P < 0.05) and meningiomas (correlation coefficient r = 0.779; P < 0.001). These findings thus suggest that VEGF may be a positive factor in tumor angiogenesis in both human gliomas and meningiomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532545

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.

Authors:  A Bogdanov; E Marecos; H C Cheng; L Chandrasekaran; H C Krutzsch; D D Roberts; R Weissleder
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.

Authors:  P Vajkoczy; M D Menger; B Vollmar; L Schilling; P Schmiedek; K P Hirth; A Ullrich; T A Fong
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

4.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

5.  Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.

Authors:  Kunal S Patel; Sameer Kejriwal; Michel M Sun; Samasuk Thammachantha; Courtney Duong; Ann Chan; Nina Cherian; Prasanth Romiyo; Lynn K Gordon; William Yong; Madhuri Wadehra; Isaac Yang
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

6.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; Carlos J da Silva; Alberto A Gabbai; Fernando A P Ferraz; João N Stávale
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 7.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

8.  Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study.

Authors:  M A Konerding; E Fait; C Dimitropoulou; W Malkusch; C Ferri; R Giavazzi; D Coltrini; M Presta
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  Current available therapies and future directions in the treatment of malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James J Vredenburgh
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.